Cardiff Oncology Inc

CRDF10 Dec 2024
Healthcare
$2.41
+0.06 (+5.63%)
Lowest Today
$2.37
Highest Today
$2.53
Today’s Open
$2.41
Prev. Close
$2.31
52 Week High
$6.42
52 Week Low
$1.25
To Invest in Cardiff Oncology Inc

Cardiff Oncology Inc

Healthcare
CRDF10 Dec 2024
+0.06 (+5.63%)
1M
3M
6M
1Y
5Y
Low
$2.36
Day’s Range
High
$2.53
2.36
52 Week Low
$1.25
52-Week Range
52 Week High
$6.42
1.25
1 Day
-
1 Week
-5.79%
1 month return
-29.37%
3 month return
+6.08%
6 month return
-18.12%
1 Year return
+84.84%
3 Years return
-56.58%
5 Years return
+86.25%
10 Years return
-
Institutional Holdings
BlackRock Inc
5.14
Vanguard Group Inc
4.25
Vanguard Total Stock Mkt Idx Inv
2.45
iShares Russell 2000 ETF
2.18
Geode Capital Management, LLC
1.82
State Street Corp
1.63
Mccormack Advisors International
1.3

Market Status

Fundamentals
Market Cap
118.12 mln
PB Ratio
2.39
PE Ratio
0
Enterprise Value
62.14 mln
Total Assets
81.64 mln
Volume

Company Financials

Fund house & investment objective

Company Information
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Organisation
Cardiff Oncology Inc
Employees
31
Industry
Biotechnology
CEO
Dr. Mark  Erlander Ph.D.
Trading and brokerage services provided by
Technology Services provided by Motilal Oswal Financial Services:

Take your next step

Click here to see your activities